(Q41984840)

14 October 2017

Expression of CD30 in patients with acute graft-versus-host disease (English)

1 reference

14 October 2017

12

1 reference

14 October 2017

Yi-Bin Chen

1

1 reference

14 October 2017

Sean McDonough

2

1 reference

14 October 2017

Robert Hasserjian

3

1 reference

14 October 2017

Heidi Chen

4

1 reference

14 October 2017

Erin Coughlin

5

1 reference

14 October 2017

Christina Illiano

6

1 reference

14 October 2017

In Sun Park

7

1 reference

14 October 2017

Madan Jagasia

8

1 reference

14 October 2017

Thomas R Spitzer

9

1 reference

14 October 2017

Corey S Cutler

10

1 reference

14 October 2017

Robert J Soiffer

11

1 reference

14 October 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

14 October 2017

1 reference

14 October 2017

120

1 reference

14 October 2017

3

1 reference

14 October 2017

691-696

1 reference

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

14 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401221

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401221

Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401221

Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401221

CD30 expression identifies the predominant proliferating T lymphocyte population in human alloimmune responses

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401221

Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401221

A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401221

Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401221

Sirolimus for treatment of steroid-refractory acute graft-versus-host disease

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401221

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401221

Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401221

Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401221

CD30 expression identifies a functional alloreactive human T-lymphocyte subset.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3401221

CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells

18 August 2018

1 reference

12 December 2020

CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity

1 reference

12 December 2020

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

1 reference

12 December 2020

A prospective study of serum soluble CD30 in allogeneic hematopoietic stem cell transplantation

1 reference

12 December 2020

Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

1 reference

12 December 2020

CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease

1 reference

12 December 2020

10.1182/BLOOD-2012-03-415422

Identifiers

DOI

1 reference

release_ajqhse6ycjdsdiowofbjjk4sxi

14 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ajqhse6ycjdsdiowofbjjk4sxi

24 November 2022

mapped directly with Wikidata item

1 reference

14 October 2017

PubMed publication ID

22661699

1 reference